Table 6.
Therapeutic approach | Examples |
---|---|
Epigenetic regulation | Histone deacetylase inhibitors: vorinostat, panobinostat, belinostat DNA methyl transferase inhibitors: Vidaza, Dacogen |
Differentiation-inducing therapeutics | Retinoid X receptor agonists Arsenic trioxide |
Angiogenesis inhibition | Inhibition of angiogenesis: Velcade Thalomid, Revlimid |
Inhibition of signaling pathways | Tyrosine kinase inhibitors: midostaurin, lestaurtinib, sorafenib, KW-2449, AC220 Cell cycle inhibitors: ON 01910.Na Farnesyl transferase inhibitors: Zarnestra, Sarasar mTOR inhibitors: Afinitor, PI-103, temsirolimus, GSK21110183 PARP inhibitors: ABT-888 MEK1/2 inhibitors: AZD6244, AS703026, PD98059, GSK1120212 Bcl-2 inhibitors: oblimersen, obatoclax, ABT-263 XIAP inhibitor: AEG-35156 Aminopeptidase inhibitors (tosedostat) |
Modulation of drug resistance | Valspodar, zosuquidar |
Modified traditional chemotherapeutics | Nucleoside analogs: clofarabine, sapacitabine, elacytarabine Alkylating drugs: irofulven, Temodar, Onrigin Topoisomerase inhibitors: Hycamtin |
Immune therapy | Antibodies: Mylotarg, lintuzumab, Avastin, T-cell targeted therapy |